Eqis Capital Management, Inc. Protagonist Therapeutics, Inc Transaction History

Eqis Capital Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$18.49 - $25.13 $200,930 - $273,087	-10,867 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$15.19 - $22.4 $35,271 - $52,012	-2,322 Reduced 17.61%	10,867 $212,000
Q2 2020 Aug 10, 2020	SELL	$6.19 - $18.84 $24,345 - $74,097	-3,933 Reduced 22.97%	13,189 $233,000
Q1 2020 May 12, 2020	BUY	$5.4 - $9.22 $945 - $1,613	175 Added 1.03%	17,122 $141,000
Q4 2019 Jan 24, 2020	SELL	$4.69 - $13.45 $7,335 - $21,035	-1,564 Reduced 8.45%	16,947 $119,000
Q3 2019 Nov 05, 2019	SELL	$9.41 - $16.56 $16,307 - $28,698	-1,733 Reduced 8.56%	18,511 $222,000
Q2 2019 Jul 18, 2019	SELL	$8.98 - $12.96 $3,187 - $4,600	-355 Reduced 1.72%	20,244 $245,000
Q1 2019 Apr 18, 2019	SELL	$6.5 - $13.77 $37,284 - $78,984	-5,736 Reduced 21.78%	20,599 $259,000
Q4 2018 Jan 25, 2019	SELL	$6.3 - $10.44 $69,073 - $114,464	-10,964 Reduced 29.39%	26,335 $177,000
Q3 2018 Oct 17, 2018	BUY	$6.82 - $11.26 $14,772 - $24,389	2,166 Added 6.17%	37,299 $355,000
Q2 2018 Jul 27, 2018	BUY	$5.99 - $9.1 $210,446 - $319,710	35,133 New	35,133 $236,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.